Your Article Summary
Sirion Therapeutics Merges With Sytera to Develop New Treatments For Eye Disease
Corporate News Releases - The Healthcare Sales & Marketing Network, 08/17/06
Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceutical company, announced that it has completed a merger with Sytera, Inc., a biopharmaceutical firm based in La Jolla, California committed to discovering new treatments for dry AMD (age- related macular degeneration). The announcement was made jointly by Sirion President and CEO Barry Butler, and Sytera Chairman and CEO Kenneth J. Widder, M.D. The financial terms were not disclosed
| Previous Article | Next Article |
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
New graduate degree offered focusing on health care quality
National Committee for Quality Assurance (NCQA), 06/11/09
GSK Signs Deal with Concert Pharma to the Tune of $1 Billion
PharmExec, 06/04/09
Sanofi-aventis and Kyowa Hakko Kirin enter into a Collaboration and Licensing Agreement on an Anti LIGHT fully human monoclonal antibody
Sanofi-aventis, 05/15/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Erlotinib Warning
JAMA, 06/29/09
Astellas Names Head of Global R and D Operations
Astellas, 06/11/09
Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
Expert Opinion in Pharmacotherapy, 06/19/09
Article Search
Sponsor


See Latest Articles


